...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Health Services Research >Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain)
【24h】

Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain)

机译：根据加泰罗尼亚（西班牙）的患者水平分析估算肺癌的诊断和治疗费用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Assessing of the costs of treating disease is necessary to demonstrate cost-effectiveness and to estimate the budget impact of new interventions and therapeutic innovations. However, there are few comprehensive studies on resource use and costs associated with lung cancer patients in clinical practice in Spain or internationally. The aim of this paper was to assess the hospital cost associated with lung cancer diagnosis and treatment by histology, type of cost and stage at diagnosis in the Spanish National Health Service. Methods A retrospective, descriptive analysis on resource use and a direct medical cost analysis were performed. Resource utilisation data were collected by means of patient files from nine teaching hospitals. From a hospital budget impact perspective, the aggregate and mean costs per patient were calculated over the first three years following diagnosis or up to death. Both aggregate and mean costs per patient were analysed by histology, stage at diagnosis and cost type. Results A total of 232 cases of lung cancer were analysed, of which 74.1% corresponded to non-small cell lung cancer (NSCLC) and 11.2% to small cell lung cancer (SCLC); 14.7% had no cytohistologic confirmation. The mean cost per patient in NSCLC ranged from 13,218 Euros in Stage III to 16,120 Euros in Stage II. The main cost components were chemotherapy (29.5%) and surgery (22.8%). Advanced disease stages were associated with a decrease in the relative weight of surgical and inpatient care costs but an increase in chemotherapy costs. In SCLC patients, the mean cost per patient was 15,418 Euros for limited disease and 12,482 Euros for extensive disease. The main cost components were chemotherapy (36.1%) and other inpatient costs (28.7%). In both groups, the Kruskall-Wallis test did not show statistically significant differences in mean cost per patient between stages. Conclusions This study provides the costs of lung cancer treatment based on patient file reviews, with chemotherapy and surgery accounting for the major components of costs. This cost analysis is a baseline study that will provide a useful source of information for future studies on cost-effectiveness and on the budget impact of different therapeutic innovations in Spain.
机译：背景技术对治疗疾病的费用进行评估对于证明成本效益和评估新干预措施和治疗创新的预算影响是必要的。然而，在西班牙或国际上，关于肺癌患者的资源使用和成本的综合研究很少。本文的目的是通过组织学，费用类型和诊断的阶段来评估西班牙国家卫生局与肺癌诊断和治疗相关的医院费用。方法对资源使用情况进行回顾性描述性分析，并进行直接医疗费用分析。资源利用率数据是通过从九所教学医院的患者档案收集的。从医院预算影响的角度来看，每位患者的总费用和平均费用是在诊断后直至死亡的头三年内计算的。通过组织学，诊断阶段和费用类型对每位患者的总费用和平均费用进行了分析。结果共分析232例肺癌，其中非小细胞肺癌（NSCLC）占74.1％，小细胞肺癌（SCLC）占11.2％。 14.7％的患者没有细胞组织学确认。 NSCLC中每名患者的平均费用从第三阶段的13,218欧元到第二阶段的16,120欧元。主要成本成分是化学疗法（29.5％）和手术（22.8％）。疾病晚期与手术和住院护理费用的相对减少有关，但化学疗法费用增加。在SCLC患者中，有限疾病的每位患者平均费用为15418欧元，广泛疾病的平均每位患者费用为12482欧元。主要费用成分是化疗（36.1％）和其他住院费用（28.7％）。在两组中，Kruskall-Wallis检验在各个阶段之间的每位患者平均费用上均未显示出统计学上的显着差异。结论本研究基于患者档案审查提供了肺癌治疗的费用，其中化学疗法和手术是费用的主要组成部分。这项成本分析是一项基线研究，将为将来的成本效益和西班牙不同治疗创新的预算影响研究提供有用的信息来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号